Skip to content
MarketScale
‹ Back to IndustriesSciences

The Industry That is Depending on Science and Regulation to Grow

Yuran Li, Director of MS Commercial Strategies at Alternative Biomedical Solutions, plays a pivotal role in cannabis testing and method development, addressing the complexities of cannabis as a consumable product. As more states legalize cannabis, rigorous testing is necessary to ensure safety and proper labeling due to the plant's tendency to absorb harmful substances like pesticides and heavy metals.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Jason Claybrook · Alternative Biomedical SolutionsCannabinoidCannabisCannabis Testing
Share
The Industry That is Depending on Science and Regulation to Grow

Key takeaways

01

Alternative Biomedical Solutions is a pioneer in cannabis method development and testing.

02

Yuran Li emphasizes the importance of rigorous cannabis testing due to its unique absorption of pesticides and heavy metals.

03

Different states have varied laws on cannabis sales, making it essential to understand individual state regulations.

Get featured

Want MarketScale to feature Sciences?

Book a 15-minute demo and we'll map your Sciences expertise to the content buyers are searching for.

Book a demo

Yuran Li, Director, MS Commercial Strategies, Alternative Biomedical Solutions (ABS), is a biochemist by training. Still, his fascinations with physics, math, and probability have led him down some interesting paths, including some stints in the professional poker world. Lucky for ABS, he chose the science route.

Cannabis is a schedule 1 drug classification by the U.S. Federal government. As more and more states legalize it, there is a growing need for reliable testing to ensure the safety and potency of cannabis products. ABS is one of the pioneers in cannabis method development and testing. Li spoke with Jason Claybrook on some of ABS’s activities surrounding Cannabis.

Any product that people consume goes through testing to ensure their safety. “Cannabis is unique in that it’s ultimately a weed,” Li said. And it can prove quite a challenge to cultivate because the plant can soak up a lot of pesticides and other elements used for pest control. “Additionally, the Cannabis plant itself also uptakes quite a lot of heavy metals, things like arsenic and lead.” Accumulation of these pollutants can harm humans, so accurate testing is essential.

Some of the testing ABS does on Cannabis is to look for micro toxins, like mold and soil pollutants. And from a marketing and regulatory standpoint, they test for potency. In some cases, testing can help ensure that a strain grown for CBD does not contain THC. One challenge Li cautioned is every state has different guidelines, and it is essential to understand the laws governing each state where Cannabis sales are allowed.

Another aspect of lab testing that is becoming more and more important for Cannabis is label testing. As with craft beers and whiskey, labels need to back up their product’s claims. Testing ensures the strain offered on the label is the strain received by the consumer.

Breaking through ‘Pilot Purgatory’ in Innovating New Solutions

Is Cryptocurrency and Its Tech Infrastructure Ready for a Revolution?

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

JC
Jason Claybrook

Follow Sciences Insights

Get new expert content in your inbox.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Wall Street is split on Circle: TD Cowen sees 31% upside while Morgan Stanley cuts its target by 64%

Wall Street is split on Circle: TD Cowen sees 31% upside while Morgan Stanley cuts its target by 64%

Wall Street analysts are divided on Circle's valuation prospects. TD Cowen has rated Circle as a buy with a target price of $82, indicating optimism in its potential growth. Meanwhile, Morgan Stanley has significantly lowered its target to $38, questioning the utility of stablecoins.

  • 01TD Cowen set Circle's target price at $82, signaling expected growth.
  • 02Morgan Stanley reduced its target for Circle to $38, citing doubts about stablecoin use.
  • 03There is a significant split among analysts regarding Circle's financial outlook.

Aug 18, 2026

Sony and TSMC's $6.3 billion image-sensor bet signals a new era of chip co-investment

Sony and TSMC's $6.3 billion image-sensor bet signals a new era of chip co-investment

Sony and TSMC have announced a joint investment of $6.3 billion to develop next-generation image-sensor chips. This collaboration is driven by the increasing demand for AI technologies, which is influencing changes in semiconductor supply chains. The initiative is expected to have significant impacts in 2026.

  • 01Sony and TSMC are investing $6.3 billion in next-generation image-sensor chips.
  • 02The investment is motivated by rising demand for AI technologies.
  • 03The partnership is a notable example of co-investment in the semiconductor industry.

Aug 12, 2026

Myrias Optics taps photonics veteran Neil Anderson as CRO to scale flat optics into AI datacenters and AR

Myrias Optics taps photonics veteran Neil Anderson as CRO to scale flat optics into AI datacenters and AR

Myrias Optics has hired Neil Anderson, Ph.D. as the Chief Revenue Officer to spearhead the commercialization of its nanoimprint flat optics platform. The platform is intended for use in AI datacenters, augmented reality (AR), and life sciences applications. Anderson's experience in photonics is expected to aid Myrias Optics in expanding its market presence in these sectors.

  • 01Myrias Optics appointed Neil Anderson, Ph.D. as CRO to lead the commercialization of its technology.
  • 02The company focuses on nanoimprint flat optics for AI datacenters, AR, and life sciences.
  • 03Neil Anderson brings extensive photonics expertise to support Myrias Optics' growth.

Jul 31, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Experts

YL
Yuran Li

Director, MS Commercial Strategies

Alternative Biomedical Solutions (ABS)

Yuran Li is a biochemist by training with a fascination for physics, math, and probability, and has had professional experience in the poker world. At ABS, he plays a key role in cannabis method development and testing.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512